Of the 66 diabetes patient groups, 50% represent patient interests to drug regulators. The most common form of engagement is representation within governmental advisory bodies (17%). The leading activity is facilitating equitable access to healthcare (28%).
50% of respondents from Diabetes ‘Regularly’ or ‘Sometimes’ represent patient interests to drug regulators
Patient groups representing each Diabetes sub-type
66 patient groups across 9 sub-types
interactions
Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring] sensors, insulin pumps, and innovative medicines.
Local diabetes patient group, Italy
interactions
We regularly advocate for improved insulin accessibility and availability across Pakistan. In March 2024, we organised an advocacy roundtable, followed by multiple engagements with DRAP [Drug Regulatory Authority of Pakistan].
We regularly advocate for improved insulin accessibility and availability across Pakistan. In March 2024, we organized an advocacy roundtable, followed by multiple engagements with DRAP. Through these efforts, we highlighted the urgent need for the government to ensure consistent insulin access for people living with diabetes nationwide. By building strong people power and collective advocacy, we were able to drive meaningful government action. As a result, the government signed a contract for the local manufacturing of insulin, marking a major milestone in diabetes care in Pakistan. This public–private collaboration has since led to the launch of insulin products by two local pharmaceutical companies and the initiation of the Chief Minister Punjab Insulin Support Program, which is modeled after Meethi Zindagi’s Program of Insulin (POI).
National diabetes patient group, Pakistan
actions & advocacy
Engagement with the city and the wellbeing services county to extend free pharmaceutical treatment to type 2 diabetes medicines.
Yhteydenpito kaupunkiin ja hyvinvointialueeseen maksuttoman lääkehoidon ulottamiseksi myös tyypin 2 diabeteslääkkeisiin.
Regional diabetes patient group, Finland
actions & advocacy
Inclusion of medical devices — such as continuous glucose monitors and insulin pumps — on the national health insurance formulary.
연속 혈당 측정기, 인슐린 펌프 등의 의료 제품의 건강 보험 등재.
National diabetes patient group, Korea
The percentages below highlight how the 36 patient groups interact with regulators and advocate for patient interests. As respondents may be represented in more than one area, percentages may not total 100%.
interactions
12 mentions
5 mentions
4 mentions
1 mention
1 mention
1 mention
11 mentions
6 mentions
4 mentions
1 mention
3 mentions
2 mentions
1 mention
2 mentions
1 mention
1 mention
2 mentions
1 mention
1 mention
actions & advocacy
11 mentions
10 mentions
1 mention
10 mentions
7 mentions
2 mentions
1 mention
6 mentions
3 mentions
3 mentions
1 mention
1 mention
GET THE REPORT
Our research covers 2,262 patient groups representing 100 countries and 45 therapy areas. The sample report shows you the depth of analysis for a single country or therapy area. To access any other reports, please get in touch.
Visit patient-view.com to gather more information or email: Alex Wyke, alexwyke@patient-view.com
